ShenZhen Lijian Pharmaceutical Co., Ltd.

Cefepime is a broad-spectrum fourth-generation cephalosporin that achieves bactericidal effects by inhibiting the biosynthesis of bacterial cell walls. It is effective against both Gram-positive and Gram-negative bacteria, is highly resistant to hydrolysis by most beta-lactamases, and can quickly penetrate into the cells of Gram-negative bacteria. Its target molecule is penicillin-binding protein (PBP). In vitro and clinical studies have confirmed that it is active against a variety of microorganisms, including but not limited to Enterobacter, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus (only for methicillin-sensitive strains), Streptococcus pyogenes (Group A Streptococcus), Streptococcus pneumoniae, etc.

Cefepime is a broad-spectrum fourth-generation cephalosporin that achieves bactericidal effects by inhibiting the biosynthesis of bacterial cell walls. In vitro tests have shown that this product is effective against both Gram-positive and Gram-negative bacteria. This product has low affinity for beta-lactamase encoded by bacterial chromosomes, is highly resistant to hydrolysis by most beta-lactamases, and can quickly penetrate into the cells of Gram-negative bacteria. In bacterial cells, its target molecule is penicillin-binding protein (PBP).

This product is an oral third-generation cephalosporin with a broad antibacterial spectrum. It has antibacterial activity against some Gram-positive and Gram-negative bacteria, especially against Streptococcus (except Enterococcus) among Gram-positive bacteria, Pneumococcus, Gonorrhea, Branhamella, Escherichia coli, Klebsiella, Serratia, Proteus, and Haemophilus influenzae among Gram-negative bacteria. Its mechanism of action is to prevent the synthesis of bacterial cell walls. Its action point varies with the type of bacteria. It has a high affinity with PBP1 (la, lb, lc) and PBP3 among penicillin-binding proteins (PBP). This product has strong stability against β-lactamases produced by various bacteria.

This product is an oral third-generation cephalosporin with a broad antibacterial spectrum. It has antibacterial activity against some Gram-positive and Gram-negative bacteria, especially against Streptococcus (except Enterococcus) and Pneumococcus among Gram-positive bacteria, and gonococci, Branhamella, Escherichia coli, Klebsiella, Serratia, Proteus, and influenza bacilli among Gram-negative bacteria. Its mechanism of action is to prevent the synthesis of bacterial cell walls. Its action point varies with the type of bacteria. It has a high affinity with PBP1 (1a, 1b, 1c) and PBP3 among penicillin-binding proteins (PBP). This product has a strong stability against β-lactamases produced by various bacteria.

It has strong antibacterial activity against Gram-positive bacteria and also has broad-spectrum antibacterial activity against bacteria including Gram-negative bacteria. At the same time, it has strong antibacterial activity against non-fermenting Gram-negative bacteria such as Pseudomonas aeruginosa. This drug has a bactericidal effect and is stable to β-lactamase produced by various bacteria; when used for experimental infection (mice), it shows excellent therapeutic effects; it is sensitive to bacteria resistant to penicillin, other cephalosporins or aminoglycoside antibiotics, especially Pseudomonas aeruginosa. It has a strong affinity with 1A, 1B and 3 of penicillin binding protein (PBP), inhibiting the synthesis of bacterial cell wall, thereby exerting a bactericidal effect.